With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...

The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn.

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...